Condition: IBD (Inflammatory Bowel Disease) · Crohn Disease (CD) · Ulcerative Colitis (UC) · Sponsor: Shmuel Kivity, MD
This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy. Participants who have not previously received anti-TNF treatment and are about to start advanced therapy will provide a blood sample to test for the genetic markers. Participants will also undergo regular assessments of current treatment, disease activity, and inflammatory markers during follow-up.
This description comes directly from the study's public registry record.
Rony Izhar, PhD · +97237772613 · ronyi@tlvmc.gov.il
Ayal Hirsch, MD · +972535289492 · ayalh@tlvmc.gov.il
Always discuss trial participation with your own doctor first.
| Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07644117